Pharmaceutical Manufacturing – Verapamil Hydrochloride Extended-Release Tablets

The contract requires the manufacture of 240 mg extended-release tablets of Verapamil Hydrochloride in full compliance with FDA, USP, and Department of Defense standards, encompassing all stages of batch production, stringent quality control procedures, and complete regulatory documentation. The product must meet exacting pharmaceutical specifications to ensure therapeutic efficacy and safety, with all processes aligned to federal and industry benchmarks for extended-release formulations. The subcontractor is expected to deliver finished tablets that are fully traceable, properly labeled, and accompanied by comprehensive technical and compliance records for DoD review and acceptance. The procurement is issued under the Medical Supply Chain Pharma FSA, part of the Department of Defense, with a place of performance listed as FPO, zip code 34094. The opportunity was posted on August 4, 2026, with a response deadline of August 10, 2026, and falls under NAICS code 325412 for pharmaceutical preparation manufacturing. Although no set-aside provisions are specified, the nature of the contract indicates it is intended for qualified pharmaceutical manufacturers with demonstrated capability in regulated, large-scale tablet production for federal defense supply channels. All activities must adhere to strict timelines and documentation protocols to support military medical readiness and logistical integration.